Literature DB >> 18180345

Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections.

Thomas R Fritsche1, Paul R Rhomberg, Helio S Sader, Ronald N Jones.   

Abstract

Omiganan, a bactericidal and fungicidal cationic peptide being developed as a topical gel for prevention of catheter-associated infections, inhibited commonly occurring fungal pathogens including Candida spp. (106 isolates) at <or=256 microg/ml and molds (including 10 Aspergillus isolates) at <or=1,024 microg/ml. All fungi were inhibited by omiganan at concentrations well below the 1% (10,000 microg/ml) clinical formulation, including species with reduced susceptibility to azoles and echinocandins.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18180345      PMCID： PMC2258495          DOI： 10.1128/AAC.01475-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  15 in total

Review 1.  MBI-226. Micrologix/Fujisawa.

Authors:  Richard E Isaacson
Journal:  Curr Opin Investig Drugs       Date:  2003-08

2.  Omiganan pentahydrochloride (MBI 226), a topical 12-amino-acid cationic peptide: spectrum of antimicrobial activity and measurements of bactericidal activity.

Authors:  Helio S Sader; Kelley A Fedler; Robert P Rennie; Shelley Stevens; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

3.  Quality control guidelines for MIC susceptibility testing of omiganan pentahydrochloride (MBI 226), a novel antimicrobial peptide.

Authors:  Tamara R Anderegg; Thomas R Fritsche; Ronald N Jones
Journal:  J Clin Microbiol       Date:  2004-03       Impact factor: 5.948

4.  National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004.

Authors: 
Journal:  Am J Infect Control       Date:  2004-12       Impact factor: 2.918

5.  Invasive Candida species infection: the importance of adequate empirical antifungal therapy.

Authors:  Darius Armstrong-James
Journal:  J Antimicrob Chemother       Date:  2007-07-23       Impact factor: 5.790

6.  Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, barcelona, Spain, from 2002 to 2003.

Authors:  Benito Almirante; Dolors Rodríguez; Benjamin J Park; Manuel Cuenca-Estrella; Ana M Planes; Manuel Almela; Jose Mensa; Ferran Sanchez; Josefina Ayats; Montserrat Gimenez; Pere Saballs; Scott K Fridkin; Juliette Morgan; Juan L Rodriguez-Tudela; David W Warnock; Albert Pahissa
Journal:  J Clin Microbiol       Date:  2005-04       Impact factor: 5.948

7.  A randomized trial comparing povidone-iodine to a chlorhexidine gluconate-impregnated dressing for prevention of central venous catheter infections in neonates.

Authors:  J S Garland; C P Alex; C D Mueller; D Otten; C Shivpuri; M C Harris; M Naples; J Pellegrini; R K Buck; T L McAuliffe; D A Goldmann; D G Maki
Journal:  Pediatrics       Date:  2001-06       Impact factor: 7.124

8.  Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs, and attributable mortality.

Authors:  D Pittet; D Tarara; R P Wenzel
Journal:  JAMA       Date:  1994-05-25       Impact factor: 56.272

9.  Clinical-epidemiological characteristics and outcome of patients with catheter-related bloodstream infections in Europe (ESGNI-006 Study).

Authors:  P Muñoz; E Bouza; R San Juan; A Voss; J Pascau; M Desco
Journal:  Clin Microbiol Infect       Date:  2004-09       Impact factor: 8.067

10.  A European perspective on intravascular catheter-related infections: report on the microbiology workload, aetiology and antimicrobial susceptibility (ESGNI-005 Study).

Authors:  E Bouza; R San Juan; P Muñoz; J Pascau; A Voss; M Desco
Journal:  Clin Microbiol Infect       Date:  2004-09       Impact factor: 8.067
View more
  13 in total

Review 1.  Antimicrobial peptides and peptidomimetics - potent therapeutic allies for staphylococcal infections.

Authors:  Haroon Mohammad; Shankar Thangamani; Mohamed N Seleem
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

2.  Novel antimicrobial peptides with high anticancer activity and selectivity.

Authors:  Hung-Lun Chu; Bak-Sau Yip; Kuan-Hao Chen; Hui-Yuan Yu; Ya-Han Chih; Hsi-Tsung Cheng; Yu-Ting Chou; Jya-Wei Cheng
Journal:  PLoS One       Date:  2015-05-13       Impact factor: 3.240

Review 3.  Endogenous antimicrobial factors in the treatment of infectious diseases.

Authors:  Paulina Żelechowska; Justyna Agier; Ewa Brzezińska-Błaszczyk
Journal:  Cent Eur J Immunol       Date:  2017-01-24       Impact factor: 2.085

4.  Antimicrobial Peptide Omiganan Enhances Interferon Responses to Endosomal Toll-Like Receptor Ligands in Human Peripheral Blood Mononuclear Cells.

Authors:  Hendrika W Grievink; Silvana M G Jirka; Tess D Woutman; Mascha Schoonakker; Robert Rissmann; Karen E Malone; Gary Feiss; Matthijs Moerland
Journal:  Clin Transl Sci       Date:  2020-04-21       Impact factor: 4.689

5.  The mechanism of action of pepR, a viral-derived peptide, against Staphylococcus aureus biofilms.

Authors:  Sandra N Pinto; Susana A Dias; Ana F Cruz; Dalila Mil-Homens; Fabio Fernandes; Javier Valle; David Andreu; Manuel Prieto; Miguel A R B Castanho; Ana Coutinho; Ana Salomé Veiga
Journal:  J Antimicrob Chemother       Date:  2019-09-01       Impact factor: 5.790

Review 6.  Innate Inspiration: Antifungal Peptides and Other Immunotherapeutics From the Host Immune Response.

Authors:  Derry K Mercer; Deborah A O'Neil
Journal:  Front Immunol       Date:  2020-09-17       Impact factor: 7.561

7.  Candidacidal Activity of Selected Ceragenins and Human Cathelicidin LL-37 in Experimental Settings Mimicking Infection Sites.

Authors:  Bonita Durnaś; Urszula Wnorowska; Katarzyna Pogoda; Piotr Deptuła; Marzena Wątek; Ewelina Piktel; Stanisław Głuszek; Xiaobo Gu; Paul B Savage; Katarzyna Niemirowicz; Robert Bucki
Journal:  PLoS One       Date:  2016-06-17       Impact factor: 3.240

Review 8.  New Horizons in Antifungal Therapy.

Authors:  Kaila M Pianalto; J Andrew Alspaugh
Journal:  J Fungi (Basel)       Date:  2016-10-02

Review 9.  The Road from Host-Defense Peptides to a New Generation of Antimicrobial Drugs.

Authors:  Alicia Boto; Jose Manuel Pérez de la Lastra; Concepción C González
Journal:  Molecules       Date:  2018-02-01       Impact factor: 4.411

10.  Omiganan Enhances Imiquimod-Induced Inflammatory Responses in Skin of Healthy Volunteers.

Authors:  Tessa Niemeyer-van der Kolk; Salma Assil; Thomas P Buters; Melanie Rijsbergen; Erica S Klaassen; Gary Feiss; Edwin Florencia; Errol P Prens; Jacobus Burggraaf; Martijn B A van Doorn; Robert Rissmann; Matthijs Moerland
Journal:  Clin Transl Sci       Date:  2020-02-13       Impact factor: 4.689
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.